ArticlePloS one2026
Cost-effectiveness of sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer in China.
Shuo Kang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it